Overview

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo controlled phase II trial is studying how well capecitabine works when given in combination with WX-671 or when given alone in treating patients receiving first-line therapy for her2negative metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Heidelberg Pharma AG
Wilex

Collaborators:

U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command

Treatments:

Capecitabine